ShRNA-mediated NRP1 knockdown in KRAS wildtype cells increased cell viability and tumor growth by decreasing the SMAD2 phosphorylation, whereas a KRAS mutant reverses the increased viability and leads to tumor inhibition. The gene discussed is NRP1; the disease is neoplasm.